Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election without traverse of Group I in the reply filed on September 21, 2026 is acknowledged.
Groups II-III are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.
Applicant reserved the right to file a divisional or continuation application to the non-elected subject matter.
An action on the merits on claims 1-3, 5-7 and 10 (Group I) is contained herein.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-3, 5-7 and 10 are rejected under 35 U.S.C. 102 as being anticipated by Pavela Therapeutics Reports (“PTR”).
Applicant claims the following methods for treating Gorlin Syndrome:
PNG
media_image1.png
164
784
media_image1.png
Greyscale
This reference discloses Applicant’s method of claims on page 2, paragraph 1. (See Abstract and entire document). The methods read on the instant claim. Since this reference teaches the exact methods, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102.
Claims 1-3, 5-7 and 10 are rejected under 35 U.S.C. 102 as being anticipated by Pavela PTX- 367(QTORIN rapamycin).
Applicant claims the following methods for treating Gorlin Syndrome:
PNG
media_image1.png
164
784
media_image1.png
Greyscale
This reference discloses Applicant’s method of claims on page 2, paragraph 1, page 3, paragraph 1, and page 3, paragraph 3. (See Abstract and entire document). The methods read on the instant claim. Since this reference teaches the exact methods, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 1-3, 5-7 and 10 are rejected under 35 U.S.C. 103 as being unpatentable over Pavela Therapeutics Reports (“PTR”).
Applicants claim methods for treating a subject with Gorlin Syndrome according to the following:
PNG
media_image2.png
620
796
media_image2.png
Greyscale
PNG
media_image3.png
129
783
media_image3.png
Greyscale
PNG
media_image4.png
62
726
media_image4.png
Greyscale
PNG
media_image5.png
406
782
media_image5.png
Greyscale
PNG
media_image6.png
128
816
media_image6.png
Greyscale
PTR teaches methods for treating Gorlin Syndrome comprising administering a topical anhydrous rapamycin gel (PTX-367). Additionally, this reference teaches that treatment prevents or decreases the number of new basal cell carcinomas (BCCs) that develop on the skin. (See page 2 paragraph 1).
PTR does not explicitly disclose treating Gorlin Syndrome wherein the method comprises administering the rapamycin gel to the affected areas .
It would have been obvious to one having ordinary skill in the art at the time of the invention to be motivated to administer to the affected areas of the subject once daily by routine experimentation to optimize the dosing regimen. Moreover, the method of applying the topical gel to the affected area to find the most effective dosing regimen by routine experimentation in order to quantify the threshold to treat Gorlin Syndrome in a subject. Thus, one skilled in the art looking for an alternative method for Gorlin Syndrome would be motivated to modity the method of PTR. Thus, Applicant’s claims are prima facie obvious in view of the teachings of PTR.
Regarding claim 2, PTR teaches the method of treating Gorlin Syndrome in claim 1. But, PTR does not explicitly teach wherein following administration of the anhydrous rapamycin gel composition the subject does not develop a new BCC on the skin in a 6 month period once treatment as started; the subject develops no more than 2 new BCCs on the skin in about a 6 month period once treatment has started; the size of a BCC on the skin lesion has decreased; the sum diameter of a BCC lesion on the skin has decreased, or a combination thereof. However, it would have been obvious to one of ordinary skill in the art to observe administration of the anhydrous rapamycin gel composition to the subject decreases the sum diameter of a BCC lesion on the skin by routine experimentation because PTR teaches reducing BCC tumorigenesis on page 3, paragraphs 1 and 3 (i.e., “the PTX-367 is a topical gel designed to inhibit mTOR, a landmark study confirmed that the mTOR pathway is involved in BCC tumorigenesis in Gorlin Syndrome”). Thus, Applicant’s claims are prima facie obvious in view of the teachings of PTR.
Regarding claim 3, PTR teaches the method of treating Gorlin Syndrome in claim 1. But, PTR does not explicitly teach wherein following administration of the anhydrous rapamycin gel composition the subject does not develop a new BCC on the skin in a 12 month period once treatment has started; the subject develops no more than 2 new BCCs on the skin in about 12 month period once treatment has started; the subject develops no more than 1 new BCC on the skin in about a 12 month period once treatment has started; or a combination thereof. However, it would have been obvious to one of ordinary skill in the art to modify the therapeutic amount and observe after administration of the anhydrous rapamycin gel composition so that the subject does not develop a new BCC on the skin in a 12 month period once treatment has started by routine experimentation because PTR teaches reducing BCC tumorigenesis on page 3, paragraph 1 and page 3, paragraph 3. Thus, Applicant’s claims are prima facie obvious in view of the teachings of PTR.
Regarding claim 7, PTR teaches the method of treating Gorlin Syndrome in claim 1. However, PTR does not teach wherein the anhydrous rapamycin gel composition is administered once daily for at least 24 weeks. However, it would have been obvious to one of ordinary skill in the art to administer the composition once daily for at least 24 weeks aby routine experimentation to optimize the dosing regimen, and to quantify the threshold to treat Gorlin Syndrome. Thus, Applicant’s claims are prima facie obvious in view of the teachings of PTR.
Regarding claim 10, PTR teaches the method of treating Gorlin Syndrome in claim 1. However, PTR does not explicitly teach wherein the BCC is selected from the group consisting of: Superficial, Nodular , Micronodular, Infiltrative, Fibroepithelial, Basal cell carcinoma with adnexal differentiation, Basosquamous carcinoma, Keratotic or combinations thereof. However, it would have been obvious to one of ordinary skill in the art to treat various forms of BCC such as Superficial, Nodular , Micronodular, Infiltrative, Fibroepithelial, Basal cell carcinoma with adnexal differentiation, Basosquamous carcinoma, Keratotic or combinations thereof since BCC can broadly be divided into three groups based on the growth patterns (i.e., Superficial BBC, Nodular BCC etc.). Thus, Applicant’s claims are prima facie obvious in view of the teachings of PTR.
Since Applicant’s claims are prima facie obvious in view of the teachings of PTR, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103.
Conclusion
Claims 1-3, 5-7 and 10 are pending in this application. Claims 1-3, 5-7 and 10 are rejected. No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/PAUL V WARD/ Primary Examiner, Art Unit 1622